Genzyme, a Sanofi (NYSE: SNY) company, announced that new magnetic resonance imaging (MRI) data from the Lemtrada® (alemtuzumab) clinical development ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE